Palvella Therapeutics, Inc.
Every calculator, already run for PVLA
Open the full toolkit →You have the numbers on PVLA. Get the argument.
A written report on which of these readings actually decide the outcome for Palvella Therapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
15 analysts covering PVLAAnalyst Price Target Disagreement for Palvella Therapeutics, Inc.
Wall Street's bull case implies +72% from the current price; the bear case implies +30%. A 41% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for PVLA
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
PVLA — frequently asked
Is PVLA a buy right now?
Wall Street's consensus rating on Palvella Therapeutics, Inc. is Strong Buy across 15 analysts, with a mean price target of $230.53 (+47% vs. the current $157.24). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is PVLA's next earnings date?
Palvella Therapeutics, Inc. is next scheduled to report earnings around Nov 11, 2026. A full PVLA research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Palvella Therapeutics, Inc.?
Analysts covering Palvella Therapeutics, Inc. (PVLA) range from a bear-case target of $205.00 to a bull-case high of $270.00, with a mean consensus target of $230.53 across 15 analysts. The spread of $65.00 (41% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Palvella Therapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Palvella Therapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full PVLA research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Palvella Therapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.